The rapid development of targeted therapeutics against anaplastic lymphoma kinase (ALK) has already resulted in significant changes to the up‐front treatment of patients with ALK‐rearranged non‐small‐cell lung cancer (NSCLC) (Camidge et al., 2012), and a current aim is to bring these personalized therapies to the benefit of childhood cancer patients, including those with neuroblastomas that harbor point mutations of ALK (Chen et al., 2008; George et al., 2008; Janoueix‐Lerosey et al., 2008; Mosse et al., 2008). The gene discussed is ALK; the disease is non-small cell lung carcinoma.